menu
    • menu
    [{"orgOrder":0,"company":"Synaffix","sponsor":"Shanghai Miracogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugate linker","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Shanghai Miracogen","highestDevelopmentStatusID":"1","companyTruncated":"Synaffix \/ Shanghai Miracogen"},{"orgOrder":0,"company":"Synaffix","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibody-drug conjugates","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Synaffix \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ ADC Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"ProfoundBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"","sponsorNew":"Synaffix \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Synaffix"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin"},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":1,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Mersana Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugates","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Synaffix \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Genmab"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin Co."},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Emergence"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":2,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":2,"dosageForm":"","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Amgen Inc"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":0.13,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Synaffix \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.58999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Synaffix","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ ABL Bio","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/ ABL Bio"},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0.73999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ SOTIO","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/ SOTIO"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"IBI-343","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/ Innovent Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Synaffix

    Menu

    Synaffix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBI-343

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from O...

                            Details : Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates, including IBI343, a recombinant human anti-Claudin 18.2 monoclonal antibody-drug conjugate.

                            Brand Name : IBI-343

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : IBI-343

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Sotio

                            Deal Size : $740.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

                            Details : Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sotio

                            Deal Size : $740.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

                            Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : ABL Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : MacroGenics

                            Deal Size : $2,200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Synaffix Announces Expansion of ADC Collaboration with MacroGenics

                            Details : Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-cla...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : MacroGenics

                            Deal Size : $2,200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Chong Kun Dang Pharm

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline

                            Details : Under the terms of the licensing agreement, Synaffix will provide access to proprietary Antibody-Drug Conjugate technologies to CKD Pharm, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Chong Kun Dang Pharm

                            Deal Size : $132.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $2,000.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs

                            Details : Amgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads for one Antibody Drug Conjugate (ADC) program.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $2,000.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Sponsor : Hummingbird Bioscience

                            Deal Size : $150.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjuga...

                            Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Antibody-drug Conjugate-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Sponsor : Hummingbird Bioscience

                            Deal Size : $150.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Sponsor : Emergence Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

                            Details : Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $360.0 million

                            September 06, 2022

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Sponsor : Emergence Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kyowa Kirin

                            Deal Size : $176.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive...

                            Details : The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $5.0 million

                            June 30, 2022

                            Lead Product(s) : Antibody-drug Conjugate Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kyowa Kirin

                            Deal Size : $176.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Synaffix

                            Netherlands arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : MacroGenics

                            Deal Size : $586.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs

                            Details : Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-d...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 03, 2022

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : MacroGenics

                            Deal Size : $586.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth